Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.44 |
| ▸ | HPGDS | O60760 | 3/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15838010 | 0.94 | SCD5 (0.52) | SCD5CKS1BSKP1SKP2USP30 | |
| SCHEMBL15838007 | 0.89 | SCD5 (0.45) | SCD5CHRNB4CHRNA3CKS1BSKP1 | |
| SCHEMBL5131427 | 0.88 | SCD5 (0.49) | SCD5CHRNB4CHRNA3CKS1BSKP1 | |
| SCHEMBL895058 | 0.84 | CHRNB4 (0.49) | CHRNB4CHRNA3 | |
| SCHEMBL25383112 | 0.82 | GPR119 (0.46) | SCD5CKS1BSKP1SKP2USP30 | |
| SCHEMBL26387369 | 0.81 | USP2 (0.41) | SCD5USP30GPR119CYP11B2 | |
| SCHEMBL12901470 | 0.80 | USP2 (0.40) | SCD5USP30GPR119CYP11B2 | |
| SCHEMBL12901471 | 0.80 | USP2 (0.40) | SCD5USP30GPR119CYP11B2 | |
| SCHEMBL12901444 | 0.80 | USP2 (0.40) | SCD5USP30GPR119CYP11B2 | |
| SCHEMBL25110341 | 0.80 | USP2 (0.40) | SCD5USP30GPR119CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440204-B1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2440204-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | Bristol-Myers Squibb Company (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| WO-2010144647-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144647-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | SCD5 2300/4885CHRNB4 2625/4885CHRNA3 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.